Objective
* To further investigate the vaccine potential of SALSA, STARP, LSA1 and LSA3.
* To improve our understanding of the mechanisms mediating protection against P. falciparum MPES in humans.
* To investigate the potential of 10 novel MPES genes and to choose those which deserve further characterization and immunogenicity studies.
Expected Outcome
A strengthened network of EC and DC partners, with a better understanding of the critical effector mechanisms that protect humans against P. falciparum pre-erythrocytic stage parasites. From this improved understanding we expect to develop a rational strategy for human MPES vaccine development.
* Using the 4 lead antigens (Ags) SALSA, LSA1, STARP and LSA3, whose antigenicity is established, we will employ a series of antigen-presentation systems, namely lipopeptides, multiple antigen lipopep-tides, recombinant Ags adsorbed to microparticles, DNA-based immunization, in order to optimize the conditions under which defence mechanisms are induced in chimps, in Aotus against P. falciparum and in mice against P. yoelii. Where necessary improved recombinant expression systems will also be evaluated.
* Perform analysis of B, Th, CTL responses, and identify antigens targeted by mechanisms effective under in vitro conditions, so as to provide an understanding of the basis of protection and therefore develop adapted formulations.
* Develop improved in vivo and in vitro screening systems to evaluate the 4 lead Ags. Compare antigen specific immune responses in humans and in chimpanzees immunized with irradiated sporozoites. Analyze the relationship between immune responses and protective status in individuals exposed in endemic areas. Analyze in vitro with the human and chimpanzee hepatocyte model the various effector mechanisms directed to these antigens. Immunize and challenge chimpanzees, Aotus and mice. Additional studies in rodents, in immunocompromised animals reconstituted with human hepatocytes, and in exposed populations, are aimed at supplying an understanding of the immunological basis of protection in natural host-parasite combinations (P. berghei in Thamnomys, P. falciparum in humans and human hepatocytes) and particularly studying CTL activity.
* Employ the conditions of immunization defined in the above steps to investigate the potential of a further 10 novel antigens.
* Extend the "best" antigens and presentation systems, identified in these studies, mostly in chimpanzees and Aotus, to a larger groups of Aotus so as to gather statistically significant data.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology immunisation
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
75724 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.